Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder

  • Moreno‑Alcázar, Ana
  • Ribases Haro, Marta
  • Sanchez Mora, Cristina P
  • Palomar Martínez, Gloria
  • Bosch Munso, Rosa M
  • Casas Brugué, Miquel
  • Ramos-Quiroga, Josep Antoni
TDAH; Genotipatge; Imatges per ressonància magnètica, TDAH; Genotipado; Imagen de resonancia magnética, ADHD; Genotyping; Magnetic resonance imaging, Previous studies have shown that the gene encoding the adhesion G protein-coupled receptor L3 (ADGRL3; formerly latrophilin 3, LPHN3) is associated with Attention-Deficit/Hyperactivity Disorder (ADHD). Conversely, no studies have investigated the anatomical or functional brain substrates of ADGRL3 risk variants. We examined here whether individuals with different ADGRL3 haplotypes, including both patients with ADHD and healthy controls, showed differences in brain anatomy and function. We recruited and genotyped adult patients with combined type ADHD and healthy controls to achieve a sample balanced for age, sex, premorbid IQ, and three ADGRL3 haplotype groups (risk, protective, and others). The final sample (n = 128) underwent structural and functional brain imaging (voxel-based morphometry and n-back working memory fMRI). We analyzed the brain structural and functional effects of ADHD, haplotypes, and their interaction, covarying for age, sex, and medication. Individuals (patients or controls) with the protective haplotype showed strong, widespread hypo-activation in the frontal cortex extending to inferior temporal and fusiform gyri. Individuals (patients or controls) with the risk haplotype also showed hypo-activation, more focused in the right temporal cortex. Patients showed parietal hyper-activation. Disorder-haplotype interactions, as well as structural findings, were not statistically significant. To sum up, both protective and risk ADGRL3 haplotypes are associated with substantial brain hypo-activation during working memory tasks, stressing this gene’s relevance in cognitive brain function. Conversely, we did not find brain effects of the interactions between adult ADHD and ADGRL3 haplotypes., This work was supported by several grants from the Plan Nacional de I+D+i and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund (FEDER): Research Project Grant (PI11/01629, PI11/01766, PI16/01505, PI17/00289, PI18/01788, PI19/00394, PI19/00721, and PI19/01224), Miguel Servet Research Contracts (CP09/00119 and CPII15/00023 to MR, CP10/00596 to EP-C and CP14/00041 and CPII19/00009 to JR), Sara Borrell contract (CD15/00199 to CSM), PFIS contract (FI20/00047 to LF), mobility grant (MV16/00039 to CSM), Pla Estratègic de Recerca i Innovació en Salut (PERIS); Generalitat de Catalunya (MENTAL-Cat; SLT006/17/287) and the Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR, Catalonian Government (2009SGR211 and 2017SGR1461). The funding organizations played no role in the study design, data collection and analysis, or manuscript approval.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA

  • Radua, Joaquim|||0000-0003-1240-5438
  • Vieta, Eduard|||0000-0002-0548-0053
  • Shinohara, Russell
  • Kochunov, Peter
  • Quidé, Yann|||0000-0002-8569-7139
  • Green, Melissa J.
  • Weickert, Cynthia S.
  • Weickert, Thomas
  • Bruggemann, Jason
  • Kircher, Tilo|||0000-0002-2514-2625
  • Nenadić, Igor|||0000-0002-0749-7473
  • Cairns, Murray J.
  • Seal, Marc
  • Schall, Ulrich
  • Henskens, Frans
  • Fullerton, Janice M.|||0000-0003-4014-4490
  • Mowry, Bryan
  • Pantelis, Christos|||0000-0002-9565-0238
  • Lenroot, Rhoshel
  • Cropley, Vanessa
  • Loughland, Carmel
  • Scott, Rodney
  • Wolf, Daniel H.
  • Satterthwaite, Theodore D.|||0000-0001-7072-9399
  • Tan, Yunlong
  • Sim, Kang|||0000-0003-3209-9626
  • Piras, Fabrizio|||0000-0003-3566-5494
  • Spalletta, Gianfranco|||0000-0002-7432-4249
  • Banaj, Nerisa|||0000-0002-6317-8549
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Solanes, Aleix|||0000-0002-2491-200X
  • Albajes-Eizagirre, Anton
  • Canales-Rodriguez, Erick Jorge|||0000-0001-6421-2633
  • Sarro, Salvador
  • Giorgio, Annabella Di
  • Bertolino, Alessandro
  • Stäblein, Michael
  • Oertel, Viola
  • Knöchel, Christian
  • Borgwardt, Stefan
  • du Plessis, Stefan
  • Yun, Je-Yeon|||0000-0002-5531-2410
  • Kwon, Jun Soo|||0000-0002-1060-1462
  • Dannlowski, Udo|||0000-0002-0623-3759
  • Hahn, Tim|||0000-0002-8929-4134
  • Grotegerd, Dominik
  • Alloz, Clara
  • Arango, Celso|||0000-0003-3382-4754
  • Janssen, Joost|||0000-0001-7613-2067
  • Díaz-Caneja, Covadonga M.|||0000-0001-8538-3175
  • Jiang, Wenhao
  • Calhoun, Vince
  • Ehrlich, Stefan|||0000-0003-2132-4445
  • Yang, Kun
  • Cascella, Nicola G.
  • Takayanagi, Yoichiro
  • Sawa, Akira
  • Tomyshev, Alexander
  • Lebedeva, Irina
  • Kaleda, Vasily
  • Kirschner, Matthias
  • Hoschl, Cyril
  • Tomecek, David
  • Skoch, Antonin
  • van Amelsvoort, Therese
  • Bakker, Geor
  • James, Anthony|||0000-0002-2742-8328
  • Preda, Adrian
  • Weideman, Andrea
  • Stein, Dan J.|||0000-0001-7218-7810
  • Howells, Fleur
  • Uhlmann, Anne|||0000-0002-1753-7811
  • Temmingh, Henk
  • López-Jaramillo, Carlos
  • Díaz-Zuluaga, Ana M..
  • Fortea, Lydia|||0000-0001-6778-2316
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Solana, Elisabeth|||0000-0001-7973-2439
  • Llufriu, Sara|||0000-0003-4273-9121
  • Jahanshad, Neda|||0000-0003-4401-8950
  • Thompson, Paul
  • Turner, Jessica A.
  • van Erp, Theo
A common limitation of neuroimaging studies is their small sample sizes. To overcome this hurdle, the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium combines neuroimaging data from many institutions worldwide. However, this introduces heterogeneity due to different scanning devices and sequences. ENIGMA projects commonly address this heterogeneity with random-effects meta-analysis or mixed-effects mega-analysis. Here we tested whether the batch adjustment method, ComBat, can further reduce site-related heterogeneity and thus increase statistical power. We conducted random-effects meta-analyses, mixed-effects mega-analyses and ComBat mega-analyses to compare cortical thickness, surface area and subcortical volumes between 2897 individuals with a diagnosis of schizophrenia and 3141 healthy controls from 33 sites. Specifically, we compared the imaging data between individuals with schizophrenia and healthy controls, covarying for age and sex. The use of ComBat substantially increased the statistical significance of the findings as compared to random-effects meta-analyses. The findings were more similar when comparing ComBat with mixed-effects mega-analysis, although ComBat still slightly increased the statistical significance. ComBat also showed increased statistical power when we repeated the analyses with fewer sites. Results were nearly identical when we applied the ComBat harmonization separately for cortical thickness, cortical surface area and subcortical volumes. Therefore, we recommend applying the ComBat function to attenuate potential effects of site in ENIGMA projects and other multi-site structural imaging work. We provide easy-to-use functions in R that work even if imaging data are partially missing in some brain regions, and they can be trained with one data set and then applied to another (a requirement for some analyses such as machine learning).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials

  • Taipale, Heidi
  • Schneider-Thoma, Johannes
  • Pinzón-Espinosa, Justo|||0000-0002-3084-7793
  • Radua, Joaquim|||0000-0003-1240-5438
  • Efthimiou, Orestis
  • Vinkers, Christiaan H.|||0000-0003-3698-0744
  • Mittendorfer-Rutz, Ellenor
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Pintor Pérez, Luis|||0000-0002-8730-7296
  • Tanskanen, Antti
  • Tomlinson, Anneka
  • Fusar-Poli, Paolo|||0000-0003-3582-6788
  • Cipriani, Andrea
  • Vieta, Eduard|||0000-0002-0548-0053
  • Leucht, Stefan
  • Tiihonen, Jari
  • Luykx, Jurjen J.|||0000-0002-6439-2774
This cohort study quantifies the proportion of real-world individuals with schizophrenia spectrum disorders who would be ineligible for participation in randomized clinical trials and explores whether clinical outcomes differ between eligible and ineligible individuals. What percentage of patients with schizophrenia in the real world are represented in randomized clinical trials (RCTs) and do their outcomes differ from those not represented in RCTs? In this study of 25 259 real-world individuals with diagnoses of schizophrenia spectrum disorders recorded in national patient registries in Finland and Sweden, about a fifth were represented in RCTs and their outcomes were better than of those individuals with schizophrenia not meeting RCT inclusion criteria. Future research should consider the heterogeneity of individuals with schizophrenia and the patient groups typically ineligible for participation; RCTs may become more inclusive by representing a broader spectrum of individuals with schizophrenia and by targeting specific currently underrepresented groups. Most evidence about efficacy and safety of antipsychotics in schizophrenia spectrum disorders relies on randomized clinical trials (RCTs). However, owing to their strict eligibility criteria, RCTs represent only a part of the real-world population (ie, unselected patients seen in everyday clinical practice), which may result in an efficacy-effectiveness gap. To quantify the proportion of real-world individuals with schizophrenia spectrum disorders who would be ineligible for participation in RCTs, and to explore whether clinical outcomes differ between eligible and ineligible individuals. This study applied eligibility criteria typically used in RCTs for relapse prevention in schizophrenia spectrum disorders to real-world populations. Individuals with diagnoses of schizophrenia spectrum disorders recorded in national patient registries in Finland and Sweden were identified. Individuals who had used antipsychotics continuously for 12 weeks in outpatient care were selected. Individuals were followed up for up to 1 year while they were receiving maintenance treatment with any second-generation antipsychotic (excluding clozapine). Follow-up was censored at treatment discontinuation, initiation of add-on antipsychotics, death, and end of database linkage. Proportions of RCT-ineligible individuals with schizophrenia spectrum disorders owing to any and specific RCT exclusion criteria. The risk of hospitalization due to psychosis within 1-year follow-up in ineligible vs eligible persons were compared using hazard ratios (HR) and corresponding 95% CIs. The mean (SD) age in the Finnish cohort (n = 17 801) was 47.5 (13.8) years and 8972 (50.4%) were women; the mean (SD) age in the Swedish cohort (n = 7458) was 44.8 (12.5) years and 3344 (44.8%) were women. A total of 20 060 individuals (79%) with schizophrenia spectrum disorders would be ineligible for RCTs (Finnish cohort: 14 221 of 17 801 [79.9%]; Swedish cohort: 5839 of 7458 [78.3%]). Most frequent reasons for ineligibility were serious somatic comorbidities and concomitant antidepressant/mood stabilizer use. Risks of hospitalization due to psychosis was higher among ineligible than eligible individuals (Finnish cohort: 18.4% vs 17.2%; HR, 1.14 [95% CI, 1.04-1.24]; Swedish cohort: 20.1% vs 14.8%; HR, 1.47 [95% CI, 1.28-1.92]). The largest risks of hospitalization due to psychosis were observed in individuals ineligible owing to treatment resistance, tardive dyskinesia, and history of suicide attempts. Finally, with more ineligibility criteria met, larger risks of hospitalization due to psychosis were observed in both countries. RCTs may represent only about a fifth of real-world individuals with schizophrenia spectrum disorders. Underrepresented (ineligible) patients with schizophrenia spectrum disorders have moderately higher risks of admission due to psychosis while receiving maintenance treatment than RCT-eligible patients. These findings set the stage for future studies targeting real-world populations currently not represented by RCTs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Optimal opportunistic screening of atrial fibrillation using pulse palpation in cardiology outpatient clinics, Who and how

  • Bañeras, Jordi|||0000-0002-7395-0862
  • Pariggiano, Ivana
  • Ródenas-Alesina, Eduard|||0000-0003-1638-7820
  • Oristrell, Gerard|||0000-0003-3217-987X
  • Escalona Silva, Roxana Andreina
  • Miranda, Berta|||0000-0003-1617-1050
  • Rello, Pau|||0000-0001-9800-7152
  • Soriano-Colomé, Toni|||0000-0002-2121-6084
  • Gordon, Blanca
  • Belahnech, Yassin|||0000-0003-0723-1023
  • Calabrò, Paolo|||0000-0002-5018-830X
  • García-Dorado, David|||0000-0002-1126-1279
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
  • Radua, Joaquim|||0000-0003-1240-5438
Atrial fibrillation (AF) remain a prevalent undiagnosed condition frequently encountered in primary care. We aimed to find the parameters that optimize the diagnostic accuracy of pulse palpation to detect AF. We also aimed to create a simple algorithm for selecting which individuals would benefit from pulse palpation and, if positive, receive an ECG to detect AF. Nurses from four Cardiology outpatient clinics palpated 7,844 pulses according to a randomized list of arterial territories and durations of measure and immediately followed by a 12-lead ECG, which we used as the reference standard. We calculated the sensitivity and specificity of the palpation parameters. We also assessed whether diagnostic accuracy depended on the nurse's experience or on a list of clinical factors of the patients. With this information, we estimated the positive predictive values and false omission rates according to very few clinical factors readily available in primary care (age, sex, and diagnosis of heart failure) and used them to create the algorithm. The parameters associated with the highest diagnostic accuracy were palpation of the radial artery and classifying as irregular those palpations in which the nurse was uncertain about pulse regularity or unable to palpate pulse (sensitivity = 79%; specificity = 86%). Specificity decreased with age. Neither the nurse's experience nor any investigated clinical factor influenced diagnostic accuracy. We provide the algorithm to select the ≥40 years old individuals that would benefit from a pulse palpation screening: a) do nothing in <60 years old individuals without heart failure; b) do ECG in ≥70 years old individuals with heart failure; c) do radial pulse palpation in the remaining individuals and do ECG if the pulse is irregular or you are uncertain about its regularity or unable to palpate it. Opportunistic screening for AF using optimal pulse palpation in candidate individuals according to a simple algorithm may have high effectiveness in detecting AF in primary care
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, Aleix|||0000-0002-2491-200X
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Janssen, Joost|||0000-0001-7613-2067
  • Amoretti, Silvia|||0000-0001-6017-2734
  • Lobo, Antonio|||0000-0002-9098-655X
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Arango, Celso|||0000-0003-3382-4754
  • Vieta, Eduard|||0000-0002-0548-0053
  • Castro-Fornieles, Josefina|||0000-0003-0632-2687
  • Bergé Baquero, Daniel|||0000-0003-2544-1016
  • Albacete, Auria|||0000-0003-4156-4972
  • Giné Serven, Eloi|||0000-0002-3130-5566
  • Parellada, Mara|||0000-0001-7977-3601
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Radua, Joaquim|||0000-0003-1240-5438
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18-24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients

  • Solana, Elisabeth|||0000-0001-7973-2439
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Lopez-Soley, Elisabet
  • Radua, Joaquim|||0000-0003-1240-5438
  • Sola-Valls, Nuria
  • Montejo, Carmen
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Pulido-Valdeolivas, Irene|||0000-0003-0188-2458
  • Sepúlveda, Maria
  • Andorra, Magí
  • Berenguer, Juan|||0000-0001-8541-8200
  • Villoslada, P.|||0000-0002-8735-6119
  • Martinez-Lapiscina, E.H.
  • Prados Carrasco, Ferran|||0000-0002-7872-0142
  • Saiz, Albert|||0000-0002-5793-8791
  • Fortea, Juan|||0000-0002-1340-638X
  • Llufriu, Sara|||0000-0003-4273-9121
The spatio-temporal characteristics of grey matter (GM) impairment in multiple sclerosis (MS) are poorly understood. We used a new surface-based diffusion MRI processing tool to investigate regional modifications of microstructure, and we quantified volume loss in GM in a cohort of patients with MS classified into three groups according to disease duration. Additionally, we investigated the relationship between GM changes with disease severity. We studied 54 healthy controls and 247 MS patients classified regarding disease duration: MS1 (less than 5 years, n = 67); MS2 (5-15 years, n = 107); and MS3 (more than15 years, n = 73). We compared GM mean diffusivity (MD), fractional anisotropy (FA) and volume between groups, and estimated their clinical associations. Regional modifications in diffusion measures (MD and FA) and volume did not overlap early in the disease, and became widespread in later phases. We found higher MD in MS1 group, mainly in the temporal cortex, and volume reduction in deep GM and left precuneus. Additional MD changes were evident in cingulate and occipital cortices in the MS2 group, coupled to volume reductions in deep GM and parietal and frontal poles. Changes in MD and volume extended to more than 80% of regions in MS3 group. Conversely, increments in FA, with very low effect size, were observed in the parietal cortex and thalamus in MS1 and MS2 groups, and extended to the frontal lobe in the later group. MD and GM changes were associated with white matter lesion load and with physical and cognitive disability. Microstructural integrity loss and atrophy present differential spatial predominance early in MS and accrual over time, probably due to distinct pathogenic mechanisms that underlie tissue damage.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder

  • Moreno‑Alcázar, Ana
  • Ribases Haro, Marta
  • Sanchez Mora, Cristina P
  • Palomar Martínez, Gloria
  • Bosch Munso, Rosa M
  • Casas Brugué, Miquel
  • Ramos-Quiroga, Josep Antoni
TDAH; Genotipatge; Imatges per ressonància magnètica, TDAH; Genotipado; Imagen de resonancia magnética, ADHD; Genotyping; Magnetic resonance imaging, Previous studies have shown that the gene encoding the adhesion G protein-coupled receptor L3 (ADGRL3; formerly latrophilin 3, LPHN3) is associated with Attention-Deficit/Hyperactivity Disorder (ADHD). Conversely, no studies have investigated the anatomical or functional brain substrates of ADGRL3 risk variants. We examined here whether individuals with different ADGRL3 haplotypes, including both patients with ADHD and healthy controls, showed differences in brain anatomy and function. We recruited and genotyped adult patients with combined type ADHD and healthy controls to achieve a sample balanced for age, sex, premorbid IQ, and three ADGRL3 haplotype groups (risk, protective, and others). The final sample (n = 128) underwent structural and functional brain imaging (voxel-based morphometry and n-back working memory fMRI). We analyzed the brain structural and functional effects of ADHD, haplotypes, and their interaction, covarying for age, sex, and medication. Individuals (patients or controls) with the protective haplotype showed strong, widespread hypo-activation in the frontal cortex extending to inferior temporal and fusiform gyri. Individuals (patients or controls) with the risk haplotype also showed hypo-activation, more focused in the right temporal cortex. Patients showed parietal hyper-activation. Disorder-haplotype interactions, as well as structural findings, were not statistically significant. To sum up, both protective and risk ADGRL3 haplotypes are associated with substantial brain hypo-activation during working memory tasks, stressing this gene’s relevance in cognitive brain function. Conversely, we did not find brain effects of the interactions between adult ADHD and ADGRL3 haplotypes., This work was supported by several grants from the Plan Nacional de I+D+i and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund (FEDER): Research Project Grant (PI11/01629, PI11/01766, PI16/01505, PI17/00289, PI18/01788, PI19/00394, PI19/00721, and PI19/01224), Miguel Servet Research Contracts (CP09/00119 and CPII15/00023 to MR, CP10/00596 to EP-C and CP14/00041 and CPII19/00009 to JR), Sara Borrell contract (CD15/00199 to CSM), PFIS contract (FI20/00047 to LF), mobility grant (MV16/00039 to CSM), Pla Estratègic de Recerca i Innovació en Salut (PERIS); Generalitat de Catalunya (MENTAL-Cat; SLT006/17/287) and the Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR, Catalonian Government (2009SGR211 and 2017SGR1461). The funding organizations played no role in the study design, data collection and analysis, or manuscript approval.